Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + VRD in Newly Diagnosed Standard-Risk Multiple Myeloma
NCT05088330Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: rate of minimal residual disease negativity at 24 weeks. Status: unknown.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05088330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088330.